Lantern Pharma Inc.
09/23/2025 | Press release | Distributed by Public on 09/23/2025 14:46
Proxy Results (Form 8-K)
Item 5.07 Submission of Matters to a Vote of Security Holders.
On September 19, 2025, Lantern Pharma Inc. (the "Company") held its 2025 Annual Meeting of Stockholders, for the purposes of:
| ● | Electing six directors, each to serve until our 2026 Annual Meeting of Stockholders; | |
| ● | Approving the one-time repricing of certain stock options granted under the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended; and | |
| ● | Ratifying the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. |
All of the persons nominated to serve on our board of directors, namely Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Lee T. Schalop and David S. Silberstein, were elected to our board of directors, with shares voted as follows:
| Name | For | Withheld |
Broker Non-Vote |
|||||||||
| Donald Jeff Keyser | 2,213,848 | 32,958 | 5,189,274 | |||||||||
| Panna Sharma | 2,212,199 | 34,607 | 5,189,274 | |||||||||
| Vijay Chandru | 2,202,401 | 44,405 | 5,189,274 | |||||||||
| Maria Maccecchini | 2,214,833 | 31,973 | 5,189,274 | |||||||||
| Lee T. Schalop | 2,213,670 | 33,136 | 5,189,274 | |||||||||
| David S. Silberstein | 2,213,088 | 33,718 | 5,189,274 | |||||||||
Our stockholders approved the one-time repricing of certain stock options granted under the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended, with shares voted as follows:
| For | 1,458,333 | |||
| Against | 758,870 | |||
| Abstain | 29,603 | |||
| Broker Non-Votes | 5,189,274 |
In addition, our stockholders ratified the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025, with shares voted as follows:
| For | 7,365,922 | |||
| Against | 43,732 | |||
| Abstain | 26,426 |
There were no broker non-votes on the ratification of our independent registered public accounting firm.
Lantern Pharma Inc. published this content on September 23, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 23, 2025 at 20:46 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]